Ceryvyn Therapeutics Limited (ASX:CYV)
Australia · Delayed Price · Currency is AUD 0.0100
0.00 (0.00%)
Sep 18, 2026, 4:10 PM AEST
Ceryvyn Therapeutics Income Statement
Financials in millions AUD. Fiscal year is July - June.
Millions AUD. Fiscal year is Jul - Jun.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Operating Revenue | 0 | 0.04 | 0.19 | 0.16 | 0.13 |
Other Revenue | - | 0.19 | 0.21 | 0.42 | 0.16 |
| 0 | 0.23 | 0.39 | 0.58 | 0.29 | |
Revenue Growth | -99.56% | -41.94% | -32.16% | 100.42% | 126.61% |
Cost of Revenue | - | - | - | - | 0.23 |
Gross Profit | 0 | 0.23 | 0.39 | 0.58 | 0.06 |
Selling, General & Admin | 9.63 | 47.58 | 23.37 | 32.23 | 25.76 |
Research & Development | 2.15 | 192.58 | 263.84 | 193.25 | 114.16 |
Other Operating Expenses | 0.17 | 1.85 | 0.72 | 0.51 | 0.25 |
Operating Expenses | 11.95 | 242.01 | 287.93 | 225.99 | 140.17 |
Operating Income | -11.95 | -241.78 | -287.53 | -225.41 | -140.12 |
Interest Expense | -11.06 | -71.98 | -45.36 | -20.23 | -0.04 |
Interest & Investment Income | 1.04 | 8.49 | 5.09 | 4.85 | 0.34 |
Currency Exchange Gain (Loss) | -4.94 | -0.44 | -0.16 | -0.73 | -4.08 |
Other Non Operating Income (Expenses) | 357.14 | 43.83 | -16.24 | 18.48 | 0.04 |
EBT Excluding Unusual Items | 330.24 | -261.87 | -344.21 | -223.04 | -143.86 |
Pretax Income | 330.24 | -261.87 | -344.21 | -223.04 | -143.86 |
Income Tax Expense | -0.21 | -10.73 | -14.11 | -8.9 | -9.14 |
Earnings From Continuing Operations | 330.45 | -251.15 | -330.1 | -214.14 | -134.72 |
Net Income | 330.45 | -251.15 | -330.1 | -214.14 | -134.72 |
Net Income to Common | 330.45 | -251.15 | -330.1 | -214.14 | -134.72 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 1,350 | 1,225 | 638 | 443 | 352 |
Shares Outstanding (Diluted) | 1,350 | 1,225 | 638 | 443 | 352 |
Shares Change | 10.23% | 91.90% | 44.18% | 25.91% | 9.71% |
EPS (Basic) | 0.24 | -0.21 | -0.52 | -0.48 | -0.38 |
EPS (Diluted) | 0.24 | -0.21 | -0.52 | -0.48 | -0.38 |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Jun '22 Jun 30, 2022 |
Free Cash Flow | -12.5 | -244.76 | -241.38 | -181.25 | -103.56 |
Free Cash Flow Per Share | -0.01 | -0.20 | -0.38 | -0.41 | -0.29 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 19.35% |
Operating Margin | -1194700.00% | -106042.98% | -73222.06% | -38939.90% | -48510.38% |
Profit Margin | 33044500.00% | -110151.75% | -84061.75% | -36992.02% | -46640.70% |
Free Cash Flow Margin | -1249800.00% | -107348.68% | -61468.64% | -31310.17% | -35854.29% |
EBITDA | -11.94 | -241.77 | -287.5 | -225.39 | -140.1 |
D&A For EBITDA | 0.01 | 0.01 | 0.03 | 0.03 | 0.02 |
EBIT | -11.95 | -241.78 | -287.53 | -225.41 | -140.12 |
Revenue as Reported | 0 | 0.23 | - | - | - |